FierceBiotech 2025-12-18 Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A
FierceBiotech 2025-12-18 Verge Genomics drops sole clinical candidate in return to AI drug discovery roots
FierceBiotech 2025-12-18 Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success
FierceBiotech 2025-12-18 After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3
FierceBiotech 2025-12-18 Lindus Health and Quotient team up to create one-stop shop for early to mid-stage trials
FierceBiotech 2025-12-17 Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road
FierceBiotech 2025-12-17 Norgine gets in on Vir's hepatitis D program with €550 European licensing pact
FierceBiotech 2025-12-17 Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay
FierceBiotech 2025-12-17 Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst
FierceBiotech 2025-12-17 Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team
FierceBiotech 2025-12-17 Harbour BioMed docks with BMS in antibody discovery, development deal worth up to $1.1B
FierceBiotech 2025-12-17 Medtronic rolls out new peripheral thrombectomy system while making advances in brain bleeds
FierceBiotech 2025-12-17 Nektar claims phase 2 alopecia success after excluding patients who ‘should never have been enrolled’